Biopharma companies want FDA to apply a single evidentiary standard to two types of drug manufacturer communications.
In comments on two agency draft guidances, industry groups and individual companies urge FDA to harmonize its evidentiary standards for medical product communications that are consistent with approved
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?